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Objectives: The aim of the study is to analyze the burden of chronic diseases 
on public health care expenditures using pharmaceutical data regarding about 2 
million individuals. MethOds: Data come from the administrative database of 
the third Belgian health insurance funds. Without explicit diagnoses of diseases 
in the database, chronic diseases are mainly estimated using drugs prescription 
(reimbursed medications only) for a treatment of at least 90 days/year. A multi-
variate linear model based on the OLS method is used to analyse the impact of 
23 chronic diseases on health care expenditures, while controlling for age, sex, 
marital and social status, share of hospital expenditures, residential areas and year 
of death. Results: Monthly average health care costs for people with one or more 
chronic conditions is 6 times greater than the ones without any chronic conditions 
(€ 423 vs. € 71). All chronic diseases (except psoriasis) have a significant impact on 
health care (at 1% level). The last months of life, developing or living with cancer, 
chronic renal failure, rare disease and mental disorder are the factors having the 
greatest impact on monthly reimbursed health care expenditures. All things being 
equal, a person at the end of life costs more than € 2,236 per month to the health 
insurance compared to a person not at the end of life. Respectively this amounts to 
€ 3,557, € 3,008, € 2,042 and € 1,151 for people living with a rare disease, chronic renal 
failure, mental disorder and cancer. cOnclusiOns: Results found in this study 
are similar to those observed in other countries. Our findings show in particular 
that chronic diseases significantly drive health care expenditures. Using secondary 
data allows to classify chronic diseases according to the financial weights while 
controlling for characteristics of the analysed population. Results highlight the high 
financial burden of chronic diseases for public health care expenditures and allow 
decision-makers to take appropriate public health measures.
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Objectives: China’s medical insurance coverage surpassed 95% nationwide by 2011 
under three basic medical insurance schemes UEBMI, URBMI and NCMS, partly due 
to the government’s heavy investment since 2009. It is still inconclusive whether 
the increased coverage rate has improved access to care. Past studies using the 
China Health and Nutrition Survey (CHNS) focused on data before 2009. This study 
investigates effects of the three different insurance schemes on health services 
utilization after the 2009 new health reform. MethOds: An analysis was conducted 
on 2009 and 2011 data from the CHNS (sampling totally 23202 people from 9 prov-
inces). To control for confounding factors, propensity score matching models were 
developed controlling for relevant factors such as age, gender, income, educational 
level and health status. The level difference of health service utilization was com-
pared between each insured and the uninsured group. Attempts were also made to 
compare average treatment costs per episode; however the data set is incomplete 
for statistical analysis. Results: In the matched samples, the UEBMI group on 
average used 2.7% less outpatient services (p< 0.05) but 1.2% more inpatient ser-
vices than the uninsured group (p< 0.05). By contrast, the URBMI group was more 
likely to pay both outpatient and inpatient visits than the uninsured, although both 
improvements were not statistically significant (p> 0.05). People in the NCMS group 
were 5.6% less likely to use outpatient services (p< 0.05); they also tended to use 
inpatient services less (p> 0.05). cOnclusiOns: Access to care across the varying 
schemes is not equal. Differences between the UE/URBMI and the uninsured may 
be resulted from different health statuses, but also they could reflect the tendency 
among the employed to delay care seeking. The relative underutilization of care by 
the rural population points again to high co-payment requirement. More research 
is necessary to understand the interplay of care infrastructure and individual care 
utilization in China.
PHP144
PrIce negotIatIon for PHarmaceutIcals In germany: HIgH Influence 
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Objectives: To investigate quantitatively, which influence the chosen EU price 
weighting method has in a theoretical framework model of pharmaceuticals price 
negotiations. MethOds: Three components theoretically determine the reim-
bursed price of a pharmaceutical under AMNOG conditions in Germany: 1) the 
level and certainty of added benefit, 2) prices of comparable pharmaceuticals 
in Germany and 3) the weighted EU price level (post rebates). In a theoretical 
model the influence of various weighting methods of EU price levels on result-
ing reimbursement was investigated. Results: Several weighting models for EU 
prices are theoretically feasible. When defining the 15 EU basket countries the 
German arbitration board had considered a weighting based on volume, approxi-
mated by country population size and an adjustment by purchasing power parity. 
Operationalisation of each of those factors showed a significant influence on 
results in our simulation: in several example cases a population and PPP health 
basket (Eurostat) was set as base case. Using a weighting based on GDP (in PPP) 
instead, resulted in a ~10-15% increase and based on Eurostat general goods 
basket (in PPP) in a ~20-25% increase in the calculated average EU price level. 
Actual observed EU drug volumes appeared to rather support such cases than 
the weighting based on the Eurostat PPP health basket. Which currency exchange 
rate was used, e.g. yearly vs. daily, Eurostat vs. other sources, had only a minor 
influence in most constellations. The launched country basket showed an overall 
high impact, with a frequently high importance of the U. K. as an EU country being 
launched relatively early. cOnclusiOns: The chosen weighting method of EU 
prices has a high impact on results of EU average price, which is an important 
component of German price negotiations. No undisputed method exists at the 
time of market entry.
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Objectives: The payer’s perspective is considered after a drug has been 
granted market access and launched. This is often too late as payers may not 
want to reimburse expensive drugs, especially if the current gold standard is 
cost effective compared to alternatives. This is mostly encountered if the drug 
was, during the clinical trials, compared to sub-standard comparators. This 
research aims to establish whether there are interventions to consider during a 
drug development cycle, and how, by using Key Intervention Points, a drug can 
be successful in the market. The first in a series of questions aims to define what 
exactly market access is. MethOds: A literature review was conducted on Ovid 
MEDLINE to establish a whether a clear and internationally validated definition 
of market access has been proposed. Included were articles and/or reviews con-
cerning market access of pharmaceuticals for human use published from January 
1999 to present day. Results: Market access can be thought of as either gain-
ing regulatory approval from bodies such as Food and Drug Administration or 
European Medicines Agency to make a drug available to patients, or as develop-
ing a drug that achieves blockbuster status through successful reimbursement, 
either through a high number of sales, or a higher-than-competitor premium 
price. Regulatory approval and reimbursement are often thought of as being inher-
ently different, yet both share the central principle of balancing the benefits and 
harms in deciding availability of drugs. The main difference between regulatory 
approval and reimbursement is the scope of benefits and harm, and the popu-
lation they consider. cOnclusiOns: Market access is difficult to define, with 
different opinions and perspectives. There currently lacks a clear, internationally 
validated method of defining exactly what it market access entails, and what it 
means to have successfully achieved it. There is a need to definitively define this 
important concept.
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Objectives: This analysis aims at presenting different market access path-
ways of Medical Nutrition (MN) products in the US, France, Germany and the 
UK. MethOds: Systematic review of submission processes for MN and food 
for special medical purpose (FSMP), combined with experience of the authors 
from previous research on health economics, Market Access and reimburse-
ment. Results: When considering MN delivered in the ambulatory care setting, 
only in France, innovative MN presenting with therapeutic value faces the medi-
cal device reimbursement process. In the UK, the process is handled by the ACBS 
and focus mainly on clinical outcome and safety; additionally this process sets 
a reimbursed price. In the US and Germany, there are reimbursed categories for 
MN linked to composition of the product and dedicated to patients with inability 
to have their nutritional needs covered by normal food intake (set by CMS in the 
US and G-BA in Germany). Creating new reimbursed categories linked to new 
MN either bringing innovative therapeutic value or targeting new disease area is 
highly difficult in all countries. For MN delivered in hospital settings, products 
delivered enterally or orally are mainly covered by hospital budget. The budget 
can be either from the hospital’s kitchen for thickened and thickening products, 
under the diagnosis-related group funding scheme related to each countries, by 
the nutritionist budget (mainly UK and US) or by the hospital’s pharmacy budget 
for specialties. For standard products, access is obtained based on tenders. In 
long-term care and nursing home, coverage and funding are more heterogene-
ous: they vary from highly regulated reimbursed scheme based on composition of 
the products and disease area to per diem fee per patient covering both food and 
MN. cOnclusiOns: The market access pathways for granting reimbursement 
or coverage of the medical nutrition category are very heterogeneous between 
the analyzed countries.
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Abacus International, Manchester, UK
Objectives: Over the past decade increasing numbers of expensive drugs have 
entered the market, placing a financial burden on hospitals in particular. Many 
high-cost therapies require use or at least initiation in the hospital setting. Many 
European countries reimburse hospitals via diagnosis-related group (DRG) systems. 
However, DRG systems are often insufficient to cover the costs of expensive drugs. 
Here we assess how expensive drugs are funded in hospitals across markets, what 
the requirements are, and the process of additional funds being granted. MethOds: 
Publicly available documents, governmental guidelines and regulations were 
assessed to understand the different processes and requirements expensive drugs 
need to meet to receive additional funding. Countries included were the UK, France, 
Germany, Italy, Spain, the Netherlands, Sweden, Denmark, Switzerland, Austria and 
Portugal. Results: In all included countries, hospital treatments are reimbursed 
via DRG systems, and most provide additional funding for expensive drugs. There 
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is overlap in the criteria to qualify for funding. Many countries consider drugs for 
additional funding when a drug can be used in more than one indication and can-
not be grouped to a specific DRG. Other criteria identified relate to, for example, 
drug prices and indications. Some countries grant additional reimbursement for 
drugs prior to assessment by a national reimbursement process, while others only 
grant additional reimbursement after the drug has been available for a certain 
period of time and funding decisions are based on historical data. In most countries, 
additional reimbursement is considered annually. Hospitals and expert groups can 
suggest additional reimbursement for expensive drugs to the responsible author-
ity. cOnclusiOns: Many countries have adapted to the need for additional funding 
for expensive drugs, and have established systems to grant this funding to hospitals. 
There are differences in criteria to qualify for, and timelines for receiving, additional 
funding after drugs are launched.
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Objectives: Initiatives aimed at improving both the quality and efficiency of United 
States health care are commonly grouped under the broad category of “pay-for-
performance” (P4P) programs. Typically these programs award bonuses to providers 
that attain pre-determined quality and cost goals, but may also impose financial 
penalties on those that fail to meet those goals. Fueled by the Affordable Care Act, 
P4P programs have recently expanded significantly within the public sector and 
are expected to grow. This project was designed to review Medicare P4P cost meas-
ures, discuss the implications for provider prescribing patterns, and recommend 
possible alternatives. MethOds: Two P4P programs, both well known under the 
health reform law and having potential to impact a large portion of the Medicare 
population, were evaluated: 1) Accountable Care Organizations (ACO), and 2) the 
Physician Value Based Payment Modifier (VBPM). Each program’s cost measure 
components and calculation methodologies were isolated, described and evalu-
ated for the potential to influence prescribing patterns. Results: Cost measures 
for the ACO and VBPM programs are based on payments made under Medicare Part 
A (Hospital Insurance) and Medicare Part B (Supplemental Insurance) but do not 
include Medicare Part D (Prescription Drug Benefit) costs. Whether performance 
is measured against the provider’s historic costs, or compared to national bench-
marks, only Medicare Parts A and B costs are included. cOnclusiOns: Medicare 
Part D costs are not included in the cost measure calculation, thereby eliminating 
prescription drug expense from the performance rating. This methodology may 
encourage providers to shift Part B drug costs to Part D, thus limiting patient access 
to therapies that may only be covered under Medicare Part B.
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Objectives: To provide an up-to-date description and comparative analysis of pric-
ing and reimbursement policies in South-Eastern Europe (SEE), and to identify fac-
tors influencing reimbursement decisions. MethOds: Payers and decision makers 
in Slovenia, Croatia, Romania and Bulgaria were interviewed by questionnaire. An 
additional literature survey covered country-specific legislation and publications 
(PubMed 2009–2014), and relevant documents from web sources including national 
hospital insurance funds, drug agencies, ministries of health, Eurostat, pharmacoeco-
nomic and outcomes research conference proceedings, the Organisation for Economic 
Co-operation and Development, and Business Monitor International. Results: The 
four countries spent 5.1%–8.8% of gross domestic product on health in 2012. Price 
controls are commonly used, applied via negotiation with marketing authorisation 
holders or indirectly through the application of copayments. Key policies are based 
on international and internal reference pricing. Bulgaria, Romania and Slovenia 
base pricing on the lowest manufacturing or retail price, while Croatia uses average 
pricing. Reimbursement requires demonstration of clinical and economical benefits 
over current standard therapy. When the importance of benefits are recognised and 
recommendations from reference health technology assessment authorities in 
Europe are published, budget impact analyses focusing on key drivers such as target 
population and price are applied. Cost containment mechanisms are also applied, 
including net price negotiation, rationing, decision postponement, payback, claw-
back and risk sharing, with the aim of protecting overall budgets. Legislative changes 
to pricing and reimbursement systems are very common. Out-of-pocket expenses 
in Romania and Bulgaria are among the highest in Europe, while the reimbursed: 
retail price difference is largely covered by supplementary insurance in Slovenia and 
Croatia. cOnclusiOns: The middle/lower income SEE countries use reference pric-
ing, and have some of the lowest prices in the European Union. Reimbursement of 
innovative drugs is restricted, there are downward trends in pricing, and risk-sharing 
agreements based on outcomes are finance-driven.
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Objectives: To gain a better understanding of the pricing and reimbursement pro-
cesses and evidence requirements at national, regional, and local levels with regards 
to a biologic obtaining a license in a second indication in the UK, France, Italy, and 
Spain. MethOds: In countries with a largely national system (UK, France), five 
telephone interviews were conducted; as Spain and Italy also have local and regional 
systems, 17 and 18 interviews, respectively, were conducted. Stakeholders included 
payer-advising clinicians, hospital administrators and pharmacists, regional pay-
ers, and local payers. Results: In the UK and France, pricing and reimbursement 
is agreed at a national level, with few restrictions at regional and local levels. In the 
UK, NHS England is likely to be responsible for funding of new biologics and relies 
on guidance from NICE before adopting a product in a new indication; therefore, 
demonstrating cost-effectiveness is key. In France, the ASMR issued by the transpar-
ency commission is important; funding usually is through the groupe homogéne 
de séjour. In addition to demonstrating clinical benefits, pharmacoeconomic stud-
ies may be required for high-cost drugs. In contrast, in Italy, although AIFA needs 
to approve a new product on a national level, subsequent requirements vary by 
region and sometimes specific location. Similarly, in Spain, once approved nation-
ally, regions develop their own recommendations, and local decisions are made by 
hospital formularies. Evidence requirements in Italy and Spain vary at national, 
regional, and local levels. cOnclusiOns: A biologic obtaining a license in a new 
indication must undergo the same procedure as a new product. The process and 
restrictions for biologics may be stricter than for other medications due to the 
perceived high cost. The level of national, regional, and local requirements and 
restrictions varies; it is important that appropriate evidence is submitted to deci-
sion makers at each level.
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Objectives: Medical devices, together with pharmacotherapy are supportive treat-
ment of many acute and chronic diseases. The place of their dispensing and direct 
sale is the dispenser of medical devices. Many medical devices are reimbursed from 
public health insurance funds entirely, for others, particularly advanced functional 
types of medical devices, there must the patient participate on the price or he can 
buy them according own decision. MethOds:  The target of the work was to analyse 
the data from paid databases of Slovak authority National Center for Health 
Information that collects the outputs of provided health care services. The most 
recent data were from 1.1. - 30.9.2014. Results: Referring to the Center for Health 
Information until 30.9.2013 there were 226 registered establishments that sell medical 
devices. Their specialization were dispenser of medical devices (n= 163), dispenser of 
orthopedic devices (n= 48) and dispenser of audioprotetic devices (n= 15). Expenditure 
of reimbursed medical devices from public health insurance funds amounted 
n-monthly packaging= 8,8mil and n-monthly value= 12,7 mil € . The highest shares had the 
group medical devices for incontinence and urinary retention (n-packages= 7,7 mil, 
n-packages%= 86.9, n-values= 3,9 mil € , n-value%= 30.9), the group plasters and bandag-
ing materials (n-packages= 0,5 mil, n-packages%= 6.1, n-values= 2,6mil € , n-value%= 10.2) and 
medical devices for ostomates (n-packages= 0,4 mil, n-packages%= 4.6, n-values= 1,6 mil € , 
n-value%= 8.1). Direct sale of medical devices to the patients reached n-monthly packaging= 
 0, 9 mil and n-monthly value= 1,1mil € . The highest shares had the group medical devices 
for incontinence and urinary retention (n-packages= 5,7 mil, n-packages%= 50.3, n-values= 
2, 6 mil € , n-value%= 26.2), the group plasters and bandaging materials (n-packages= 3,5 
mil, n-packages%= 30.9, n-values= 2,0 mil € , n-value%= 20.4) and medical devices for 
diabetics (n-packages= 0,5 mil, n-packages%= 4.5, n-values= 0,7 mil € , n-value%= 7.3).  
cOnclusiOns: Medical devices are reimbursed frompublic health insurance funds 
or paid by patient and their proportion constitutes 7: 1 in packages and 11: 1 in Eur.
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Objectives: Troika’s measures to support Greece’s financial recovery have tar-
geted all sectors of economy including health care. Since 2012, policy reforms have 
changed the way health care is funded, managed and delivered, and how pharma-
ceuticals are priced, accessed and reimbursed. This study examines the changes 
to the Greek system and tries to understand the wider possible impact on global 
pricing and access strategies. MethOds: To better understand the recent reforms 
we conducted a literature review of public domain sources, including the Greek 
Government Gazette, PubMed and other websites. Searches were conducted in 
English and Greek-language, and materials were translated into English. From our 
findings a road map diagram was developed, and this was validated by interviews 
with health policy experts. Results: Part of troika’s campaign to reduce public 
spending has seen the Greek government focus on pharmaceutical markets and 
introduce policies to contain costs. The drug budget for 2014 has been cut to 2 
billion euros, a billion lower than 2013. Considerable price cuts have been agreed 
on both novel and generic agents on top of clawbacks and rebates for high cost 
drugs. Prescribing is controlled through electronic prescription and physician budget 
caps. Introduction of price-volume agreements and risk sharing schemes are being 
considered, however the infrastructure to support implementation is still under 
development. Demonstrating value by health economics and outcomes research 
can still help manufacturers to achieve premiums. cOnclusiOns: With a small 
population and an ever-decreasing expenditure on health care, it is tempting to 
overlook Greece when developing a product launch strategy. However, with Greek 
drug prices being referenced by several EU and non-EU countries, ignoring Greece 
may no longer be an option, especially when considering the indirect effect on the 
big EU5 prices. Understanding the reforms and assessing the impact on launch 
sequencing will be key in developing optimal pricing strategies.
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